Evidence map›Paper›PMID 31643121›Full record

ArticleThe Kaohsiung journal of medical sciences2020

Reduction of miR-212 contributes to pituitary adenoma cell invasion via targeting c-Met.

Hong-Yan Wang, Huai-Qing Gao

Open access · goldAbstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hong-Yan WangDepartment of Neurology, Zibo Central Hospital, Zibo, Shandong Province, China.ORCID https://orcid.org/0000-0003-4673-9057
Huai-Qing GaoDepartment of Neurology, Zibo Central Hospital, Zibo, Shandong Province, China.
Central Hospital of Zibo · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aimed to evaluate the expression and role of miR-212 in the progression of pituitary adenoma (PA), thereby providing a theoretical basis and potential therapy methods for PA patients. Our data showed that miR-212 levels were significantly reduced in PA tissues than normal pituitary tissues. However, no significant difference was identified in the serum of PA patients and healthy control. In addition, the expression of miR-212 in invasive PA was significantly lower than that in noninvasive and normal pituitary tissues. Moreover, the level of miR-212 was decreased with the increase of tumor invasion. Meanwhile, the expression of miR-212 in giant adenomas was significantly lower than that in macroadenomas and microadenomas. Furthermore, inhibition of miR-212 significantly enhanced the proliferation and invasive capacity of GH3 cells. Dual luciferase reporter assay and western blot analysis confirmed that c-Met was a target gene of miR-212. More importantly, upregulation of c-Met significantly prompted PA cell proliferation mainly as a result of the enhanced level of phosphorylation of AKT. This effect could be abolished when c-Met was silenced in GH3 cells. In summary, reduced miR-212 expression in PA contributed to abnormal cancer cell proliferation and invasion mainly by targeting c-Met.

Indexed as

3' Untranslated RegionsAnimalsApoptosisBlotting, WesternCell LineCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPituitary NeoplasmsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metRatsReal-Time Polymerase Chain Reaction3' Untranslated RegionsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metc-MetinvasionmiR-212pituitary adenoma

Identifiers

PMID31643121
PMCPMC11896187
OpenAlexW2981498676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.